[Diabetology].
In 2008, two highly discussed trials regarding the impact of glycemic control in type 2 diabetes, ACCORD and AVANCE, have been published. They showed a modest benefit of optimal glycemic control on morbidity and conflicting results on mortality, with an excess in the intensive treatment group of ACCORD. However several questionable aspects can be pointed out, the most prominent being the very limited duration of the intervention. This constrasts strongly with the long-term postintervention outcomes of UKPDS, which show a persistant benefit of glycemic control during 10 years of post-trial follow-up. These findings emphasize the need for an individualized approach of type 2 diabetic patients, aiming at the best possible control of all risk factors while minimizing the risk of hypoglycemia.
Egli
Marc
M
Service d'endocrinologie, diabétologie et métabolisme CHUV, 1011 Lausanne. Marc.Egli@chuv.ch
Ruiz
Juan
J
D001786:Blood Glucose / Q000032:analysis*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000517:prevention & control*; D006801:Humans; D016032:Randomized Controlled Trials as Topic
D001786:Blood Glucose